Get the Stockscreener App
77.91
3.18%
-2.56
After Hours:
78.00
0.09
+0.12%
Kiniksa Pharmaceuticals International Plc stock is traded at $77.91, with a volume of 429.62K.
It is down -3.18% in the last 24 hours and up +2.53% over the past month.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
See More
Previous Close:
$80.47
Open:
$79.75
24h Volume:
429.62K
Relative Volume:
0.61
Market Cap:
$6.08B
Revenue:
$754.05M
Net Income/Loss:
$73.06M
P/E Ratio:
85.87
EPS:
0.9073
Net Cash Flow:
$164.23M
1W Performance:
-0.22%
1M Performance:
+2.53%
6M Performance:
+64.82%
1Y Performance:
+119.40%
1-Day Range:
$77.90
$80.43
1-Week Range:
$76.65
$81.41
52-Week Range:
$35.12
$82.94
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile
Name
Kiniksa Pharmaceuticals International Plc
Sector
Phone
(781) 431-9100
Address
105 PICCADILLY, SECOND FLOOR, LONDON
Compare KNSA vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KNSA
Kiniksa Pharmaceuticals International Plc
|
77.91 | 6.12B | 754.05M | 73.06M | 164.23M | 0.9073 |
TAK
Takeda Pharmaceutical Co Adr
|
18.45 | 57.90B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.36 | 42.89B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.60 | 43.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
75.81 | 31.00B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
487.61 | 22.35B | 3.17B | 1.29B | 1.01B | 27.09 |
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-19-26 | Initiated | Canaccord Genuity | Buy |
| Sep-29-25 | Initiated | TD Cowen | Buy |
| Mar-13-25 | Initiated | Citigroup | Buy |
| Sep-13-24 | Initiated | Jefferies | Buy |
| May-03-24 | Initiated | Wells Fargo | Overweight |
| Jun-29-20 | Reiterated | BofA Securities | Buy |
| Apr-01-20 | Initiated | BofA/Merrill | Buy |
| Mar-11-19 | Initiated | Barclays | Overweight |
| Dec-12-18 | Reiterated | Wedbush | Outperform |
| Jun-19-18 | Initiated | JMP Securities | Mkt Outperform |
View All
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News
Megna Michael R Reduces Kiniksa Holdings to 29,062 Shares Following Sale and Other Transactions - Kalkine Media
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Fall 3.2% -- What GF Score of 46 Tells Investors - GuruFocus
Kiniksa Pharmaceuticals COO Moat Ross Executes Significant Equity Transactions on September 1, 2026 - Kalkine Media
Kiniksa sets a live healthcare talk for Sept. 9 - Stock Titan
Kiniksa CFO Mark Ragosa Reports RSU Vestings, Tax Withholding Share Sale, and New Equity Grants - Kalkine Media
Kiniksa Pharmaceuticals CEO Sanj K Patel Reports RSU Vesting, Share Sale, and New Equity Grants - Kalkine Media
Kiniksa (NASDAQ: KNSA) grants 14,600 options and 3,650 RSUs to Michael Megna - Stock Titan
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael Megna Sells 4,600 Shares - MarketBeat
Kiniksa Pharmaceuticals (KNSA) gives CEO new 10-year stock option grant - Stock Titan
Kiniksa (KNSA) CEO gets new equity grants vesting over four years - Stock Titan
Kiniksa Pharmaceuticals (KNSA) awards CFO new equity - Stock Titan
Officer at Kiniksa (NASDAQ: KNSA) plans $369K stock sale - Stock Titan
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Braidwell LP - MarketBeat
Headlands Technologies LLC Purchases Shares of 18,161 Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa stock holds firm after a $243.6 million quarter - AD HOC NEWS
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Kiniksa (KNSA) Earnings Reading: The EPS Result Is Below Expectation in the Current Update; Share Move: The Market Price Advances 1.03% at the CloseProfitability Analysis - vinanet.vn
Kiniksa Director Barry D Quart Donates 2,600 Class A Shares to Donor Advised Fund - Kalkine Media
Kiniksa (NASDAQ: KNSA) director gifts 2,600 shares to donor fund - Stock Titan
Kiniksa (KNSA) Earnings Report: EPS Comes in Below Forecast in the Reported Period; Trading Move: Shares Move 2.88% Lower on the DayEarnings Revision Downgrade - vinanet.vn
Kiniksa Pharmaceuticals International PLC - TradingKey
Handelsbanken Fonder AB Makes New $1.34 Million Investment in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Pharmaceuticals (NASDAQ:KNSA): A Compelling Affordable Growth Story - ChartMill
Kiniksa Pharmaceuticals International PLC (KNSA) Shares Surge 3. - GuruFocus
Bank of America Corp DE Boosts Stake in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3 - sharewise.com
Kiniksa Pharmaceuticals International, plc Class A Revenue Breakdown – BIVA:KNSA/N - TradingView
KNSA: ARCALYST drives record growth as pipeline advances and patient access, awareness, and satisfaction rise - TradingView
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: A Promising Outlook with 28% Potential Upside - DirectorsTalk Interviews
Kiniksa Pharmaceuticals (KNSA) Holds Near $76.53 as Bulls Eye $80.36 ResistanceBPI Bull Correction - vinanet.vn
Kiniksa Pharmaceuticals International, plc Class A Actuals & Estimates (NASDAQ:KNSA) - TradingView
Does Raised 2026 Revenue Guidance Change The Bull Case For Kiniksa Pharmaceuticals International (KNSA)? - simplywall.st
Kiniksa Pharmaceuticals International, plc $KNSA Stake Raised by The Manufacturers Life Insurance Company - MarketBeat
Kiniksa Pharmaceuticals to present at Canaccord Genuity Growth Conference on August 12, 2026 - Pluang
Kiniksa’s Aug. 12 fireside chat will stream live online - Stock Titan
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference - The Manila Times
Kiniksa Pharmaceuticals International PLC (KNSA) Stock News Today - TradingKey
Kiniksa Pharmaceuticals International PLC (KNSA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kiniksa Pharmaceuticals International, plc $KNSA Shares Sold by Lazard Asset Management LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
31,391 Shares in Kiniksa Pharmaceuticals International, plc $KNSA Bought by Financial Enhancement Group LLC - MarketBeat
Kiniksa Pharmaceuticals International, plc $KNSA Shares Bought by Janus Henderson Group PLC - MarketBeat
Kiniksa Pharmaceuticals International's (NASDAQ:KNSA) Strong Earnings Are Of Good Quality - 富途牛牛
Kiniksa Pharmaceuticals (KNSA) Stock Analysis: Unlocking A 33.5% Upside Potential - DirectorsTalk Interviews
Dimensional Fund Advisors LP Purchases 128,417 Shares of Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat
ผลประกอบการ ที่แข็งแกร่งของ Kiniksa Pharmaceuticals International (NASDAQ:KNSA) เป็นผลประกอบการที่มีคุณภาพดี - Moomoo
KNSA Q2 Earnings Call Backs Higher ARCALYST Sales Outlook - Yahoo Finance
Kiniksa Pharmaceuticals International, plc (KNSA) director sells and gifts shares - Stock Titan
Kiniksa Pharmaceuticals (KNSA) Slides 5.2% to $74.14 as Key Support Level LoomsSmart Beta Flow - vinanet.vn
Kiniksa Pharmaceuticals (KNSA) Pulls Back After Recent Rally: Key Levels in FocusThematic ETF Flow - vinanet.vn
KNSA Maintained by Canaccord Genuity -- Price Target Raised to $98 - GuruFocus
Kiniksa Pharmaceuticals International Plc Stock (KNSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.66%
0.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):